Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 140,600
-1,600 (-1.13%)
At close: Nov 5, 2025
Daewoong Pharmaceutical Revenue
Daewoong Pharmaceutical had revenue of 405.45B KRW in the quarter ending June 30, 2025, with 12.45% growth. This brings the company's revenue in the last twelve months to 1.49T, up 6.38% year-over-year. In the year 2024, Daewoong Pharmaceutical had annual revenue of 1.42T with 3.44% growth.
Revenue (ttm)
1.49T
Revenue Growth
+6.38%
P/S Ratio
1.09
Revenue / Employee
905.29M
Employees
1,644
Market Cap
1.62T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.42T | 47.35B | 3.44% |
| Dec 31, 2023 | 1.38T | 95.24B | 7.44% |
| Dec 31, 2022 | 1.28T | 127.12B | 11.03% |
| Dec 31, 2021 | 1.15T | 97.55B | 9.24% |
| Dec 31, 2020 | 1.06T | -58.00B | -5.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |
Daewoong Pharmaceutical News
- 7 months ago - Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis - Business Upturn